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Iron abnormalities within the brain are associated with several rare but severe 
neurodegenerative conditions. There is growing evidence that more common systemic iron 
loading disorders such as hemochromatosis can also have important effects on the brain. To 
identify features that are common across different forms of hemochromatosis, we used 
microarray and real-time RT-PCR to assess brain transcriptome profiles of transferrin 
receptor 2 mutant mice (Tfr2
mut
), a model of a rare type of hereditary hemochromatosis, 
relative to wildtype control mice. The results were compared with our previous findings in 
dietary iron-supplemented wildtype mice and Hfe
-/-
 mice, a model of a common type of 
hereditary hemochromatosis. For transcripts showing significant changes relative to controls 
across all three models, there was perfect (100%) directional concordance (i.e. transcripts 
were increased in all models or decreased in all models). Comparison of the two models of 
hereditary hemochromatosis, which showed more pronounced changes than the dietary iron-
supplemented mice, revealed numerous common molecular effects. Pathway analyses 
highlighted changes for genes relating to long-term depression (6.8-fold enrichment, 
p=5.4x10
-7
) and, to a lesser extent, long-term potentiation (3.7-fold enrichment, p=0.01), with 
generalized reductions in transcription of key genes from these pathways, which are involved 
in modulating synaptic strength and efficacy and are essential for memory and learning. The 
agreement across the models suggests the findings are robust and strengthens previous 
evidence that iron loading disorders affect the brain. Perturbations of brain phenomena such 
as long-term depression and long-term potentiation might partly explain neurologic 
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Iron has crucial roles in brain functions such as neurotransmitter synthesis and myelination 
but abnormally high brain iron levels have been proposed to be associated with 
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease and neurodegeneration with brain iron accumulation (reviewed (Johnstone and 
Milward, 2010b)). However debate surrounds the question of whether disorders of systemic 
iron accumulation, such as hereditary hemochromatosis, can also have detrimental effects on 
the brain.  
 
Hereditary hemochromatosis is a genetic disorder characterized by iron loading in peripheral 
tissues such as the liver (Pietrangelo, 2006; Ayonrinde et al., 2008). Evidence from case 
studies suggests that some hemochromatosis patients also have abnormal iron accumulation 
in the brain, particularly in the basal ganglia (Nielsen et al., 1995; Berg et al., 2000; Rutgers 
et al., 2007) and choroid plexus, pituitary, periventricular and perivascular regions (reviewed 
(Russo et al., 2004)). However there have been few, if any, studies of brain iron levels in 
large cohorts of hemochromatosis patients. While liver damage, arthritis and diabetes are the 
most well documented clinical consequences of hemochromatosis, some clinical and 
epidemiological studies have suggested possible associations with neurologic problems, 
including extreme fatigue (Whitlock et al., 2006; Allen et al., 2008; McLaren et al., 2008) 
and severe headaches (Hagen et al., 2002; Stovner et al., 2002).  
 
Hemochromatosis is most commonly due to disease-causing polymorphisms in the HFE gene 
(Feder et al., 1996; Brissot et al., 1999; Olynyk et al., 1999), however loss-of-function 
mutations in the transferrin receptor 2 (TFR2) gene have also been demonstrated as causative 
(Camaschella et al., 2000; De Gobbi et al., 2001; Roetto et al., 2001). The TFR2 gene is 
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transcribed in two main isoforms – the full-length form (α) and a shorter form (β) (Kawabata 
et al., 1999). In the liver, the primary site of iron storage and regulation, both HFE and TFR2-
α (but not TFR2-β (Roetto et al., 2010)) are involved in regulating expression of the hormone 
peptide hepcidin, which in turn regulates dietary iron absorption (Nemeth et al., 2004). Loss-
of-function mutations in either HFE or TFR2 lead to loss of hepcidin regulation and 
inappropriate iron absorption (Ajioka et al., 2002; Bridle et al., 2003; Nemeth et al., 2005; 
Drake et al., 2007).  
 
Evidence from in vitro studies of hepatocytes has been interpreted to suggest that HFE and 
TFR2 form part of a common feedback mechanism that regulates hepcidin expression (Gao et 
al., 2009), however evidence from mice with combined deletion of Hfe and Tfr2 genes 
suggest that the HFE and TFR2 proteins are involved in parallel pathways (Wallace et al., 
2009a; Wallace et al., 2009b; Delima et al., 2012). It is not known whether HFE and TFR2 
perform similar iron regulatory functions in other parts of the body, such as the brain, nor 
whether they are involved in common or parallel pathways in non-hepatic tissues. 
 
We have previously investigated the effects of hemochromatosis on the brain by assessing the 
brain transcriptome in mouse models of dietary iron loading (Johnstone and Milward, 2010a) 
and HFE-related hemochromatosis (Hfe
-/-
 mice) (Johnstone et al., 2012a; Johnstone et al., 
2012b). While these two models show comparable liver iron loading and no detectable brain 
iron loading, the brains of Hfe
-/-
 mice show substantially more changes at the transcript level 
than dietary iron-supplemented mice, suggesting hereditary hemochromatosis has more 
widespread effects on the brain than dietary iron loading. It is unclear whether this is due to 
the chronic nature of the iron accumulation peripherally, or due to disruption of internal brain 




To investigate this further, we have assessed the brain transcriptome of Tfr2 mutant mice 
(Tfr2
mut
), another model of hereditary hemochromatosis that develops chronic iron loading, 
with the aim of delineating which brain effects are due to chronic systemic iron loading and 
which are due to gene-specific disruption within the brain. We also aimed to assess the 
replicability, in the Tfr2
mut
 model, of important findings from the Hfe
-/-
 mouse study which 




2 Experimental Procedures 
2.1 Animals 
All animal work was conducted at the University of Western Australia and all protocols were 
approved by the institutional Animal Ethics Committee. The Tfr2 mutant mouse model 
(Tfr2
mut
) has been described previously (Fleming et al., 2002; Drake et al., 2007; Chua et al., 
2010). Mice are homozygous for the Tfr2 Y245X nonsense mutation, orthologous to the 
TFR2 Y250X mutation found in human patients (Camaschella et al., 2000). Wildtype and 
Tfr2
mut
 mice were of the AKR strain, which has been shown to manifest a stronger iron 
loading phenotype than other mouse strains, with higher hepatic iron concentration and serum 
transferrin saturation (McLachlan et al., 2011). All mice were male and were fed standard 
mouse chow from weaning. At 10 weeks of age, mice were sacrificed under anesthesia (50 
mg/kg ketamine, 10 mg/kg xylazine; Troy Laboratories Pty Ltd, Smithfield, NSW, Australia) 
and perfused transcardially with isotonic saline. Brains were removed, snap-frozen in liquid 






2.2 Iron measurements  
Non-heme iron levels in brain and liver homogenates were assessed using the method of 
Kaldor (Kaldor, 1954), as described previously (Johnstone and Milward, 2010a; Johnstone et 
al., 2012a). 
 
Total brain iron levels were assessed by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES). Approximately 150 mg of homogenized brain tissue from wildtype 
controls (n=7) or Tfr2
mut
 mice (n=5) was digested with 10 ml concentrated nitric acid (69%) 
at 60ºC. Following complete solubilization of tissue, samples were heated to 95ºC until 
volume was reduced to ~1 ml. Upon cooling, samples were diluted to ~8 ml in 1% nitric acid. 
Samples were sent to the Marine and Freshwater Research Laboratory, Murdoch University, 
Australia for measurement of iron and other metals (cadmium, copper, manganese, lead, 
selenium, zinc) by ICP-AES. 
 
2.3 Western immunoblotting 
To isolate protein, whole brain tissue homogenates from wildtype mice (n=7) and Tfr2
mut
 
mice (n=5) were treated with a lysis buffer (0.5% Triton X-100, 25 mM Tris-HCl, 150 nM 
NaCl) containing 1 tablet of CompleteMini protease inhibitor cocktail (Roche Diagnostics 
GmbH, Mannheim, Germany) per 10 ml buffer. Protein concentration was quantified by 
BCA assay (Pierce, Rockford, IL, USA). Proteins (60 μg/lane) were separated by 12% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western immunoblotting and 
visualization performed as described previously (Chua et al., 2008). Ferritin was detected 
using rabbit anti-human ferritin primary antibody (1:2000; Dako, Carpinteria, CA, USA), 
which recognizes both heavy and light chains, and goat anti-rabbit IgG-HRP secondary 
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antibody (1:2000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Actin, used as a 
reference protein, was detected using a mouse anti-human primary antibody (1:1000; 
Millipore, Billerica, MA, USA) followed by goat anti-mouse IgG-HRP secondary antibody 
(1:2000; Santa Cruz Biotechnology). Images were obtained using a Versadoc imaging system 
and densitometry performed using the QuantityOne software package (Bio-Rad Laboratories, 
Hercules, CA, USA). Ferritin protein levels were quantified relative to levels of actin. 
 
2.4 Microarray 
Whole brains homogenates from biological replicates of wildtype mice (n=4) and Tfr2
mut
 
mice (n=4) were subjected to RNA isolation using TRI Reagent (Ambion, Austin, TX, USA), 
according to the manufacturer’s instructions. Following isolation, total RNA was purified and 
concentrated using the RNeasy MinElute Kit (QIAGEN, Hilden, Germany). Total RNA (500 
ng) was prepared for microarray using the Illumina TotalPrep RNA Amplification Kit 
(Ambion). 
 
The brain transcriptome was assessed using Illumina Sentrix MouseRef-8 (v1.1) BeadChip 
microarrays, which contain ~24,000 specific oligonucleotide probes. Arrays were scanned 
using the Illumina BeadArray Reader and BeadScan software. Data were analysed using 
BeadStudio v3 (Illumina, San Diego, CA, USA), with normalization by Cubic Spline and 
differential expression analysis using the Illumina Custom algorithm. This generated a list of 
probes with significant (p<0.05) differences in signal intensity between Tfr2
mut
 mice and 
wildtype controls. This probe list was then filtered by detection p-value in order to eliminate 
probes detecting non-specific signals. Probes assigned a detection p-value ≥0.01 in both 
control and Tfr2
mut
 groups were removed from further consideration. Probe annotations from 
the microarray manifest file were updated using the SOURCE database 
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(http://smd.stanford.edu/cgi-bin/source/sourceSearch), using the listed NCBI transcript 
accession numbers as the search terms. Where the accession number was no longer listed in 
the database, annotations were updated by aligning the probe sequence against the mouse 
transcriptome using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.5 Pathway classification and enrichment analysis 
Pathway enrichment analyses were performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/) (Huang da et 
al., 2009b, a). Pathway classification within DAVID used the Kyoto Encyclopedia of Genes 
and Genomes database (KEGG; http://www.genome.jp/kegg/pathway.html). We assessed 
enrichment among the list of transcripts with significantly altered levels between wildtype 
and Tfr2
mut
 groups, and also further subdivided these lists into up-regulated and down-
regulated transcripts. Enrichment statistics were adjusted by Benjamini correction. 
 
2.6 Real-time RT-PCR 
Levels of select transcripts of interest were measured by real-time RT-PCR in additional 
wildtype mice (n=8) and Tfr2
mut
 mice (n=9). Reverse transcription of 1 μg total RNA to 
complementary DNA (cDNA) was performed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). Real-time PCR was performed 
on the ABI 7500 Real Time PCR System (Applied Biosystems). Each reaction was 
performed in triplicate and contained Power SYBR Green PCR Master Mix (Applied 
Biosystems), 200 nM forward and reverse primers (Table 1) and 4.5 μl cDNA. Transcript 
levels of interest were quantified relative to transcript levels for two reference genes (Rpl13a, 
Gapdh) using the geometric mean of threshold cycle values as the reference. Student t-testing 
was used for statistical comparisons of wildtype control and Tfr2
mut






3.1 Iron measures 
Animals used in this study were aged 10 weeks, an age at which Tfr2
mut
 mice have been 
reported to manifest liver iron loading comparable to that in mild human hemochromatosis 
but no gross damage to the liver or other tissues (Drake et al., 2007). This age is the same as 
that at which changes have been observed in our previous studies of other mouse models of 
iron loading (Johnstone and Milward, 2010a; Johnstone et al., 2012a) and facilitates 
assessment of early changes occurring in response to TFR2 dysfunction, uncomplicated by 
subsequent secondary effects. 
 
As expected, liver non-heme iron levels were significantly higher (>3-fold) in Tfr2
mut
 mice 
than wildtype controls (955±73 μg Fe/g tissue vs. 307±28 μg Fe/g tissue; p<0.05). In 
contrast, Tfr2
mut
 and control mice showed no difference in brain total iron levels measured by 
ICP-AES (13.2±0.2 μg Fe/g tissue vs. 13.1±0.6 μg Fe/g tissue). Similarly, there was no 
difference in brain non-heme iron levels between the two groups (p>0.05). Measurement of 
other metals by ICP-AES revealed no difference in levels of copper, zinc and manganese, 
while levels of cadmium, lead and selenium were below the detection limits of the assay (data 
not shown). 
 
3.2 Summary of microarray results 
Levels of numerous mRNA transcripts differed significantly (p<0.05) between brains from 
Tfr2
mut
 mice and wildtype controls. In summary, of the 24,611 probes on the array, 10,835 
detected signals significantly above background levels. Of these, 742 probes, targeting 712 
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different transcripts, detected significantly altered expression in group comparisons of Tfr2
mut
 
and wildtype brain, however most of these changes (~95%) were less than 2-fold in 
magnitude. 
 
3.3 Expression of iron-related genes 
The Tfr2
mut
 mice showed few expression changes for genes relating to iron metabolism or 
regulation. Transcripts for TFR2 were detectable in wildtype brain and significantly reduced 
in Tfr2
mut
 brain (2.2-fold decrease, p=0.007), presumably due to nonsense-mediated decay. 
Other transcripts with key roles in iron metabolism or regulation, including hepcidin, showed 
either unaltered levels or were below microarray detection limits (data not shown). One 
notable exception was a significant increase in transcripts by microarray (1.3-fold increase, 
p=0.033) for ferritin light chain 1 (Ftl1), encoding an essential component of the iron storage 
protein ferritin, however this transcript level change was not validated by real-time RT-PCR 
(Fig. 1). Western immunoblotting of whole brain homogenate showed increased levels of 
total ferritin protein in Tfr2
mut
 mouse brain relative to wildtype controls (1.5-fold increase, 
p=0.01; Fig. 2), however we were unable to resolve light and heavy chain subunits. 
 
3.4 Pathway enrichment analysis 
To determine whether particular pathways were over-represented in the lists of differentially-
expressed genes, we used the online tool DAVID to classify the list of significantly altered 
transcripts into KEGG pathways and assess pathway enrichment. This list was further divided 
into two sets comprising transcripts that were i) up-regulated or ii) down-regulated, and 
enrichment assessed within these subsets. While there were no significantly enriched 
pathways among the list of up-regulated transcripts, several pathways were identified as 
significantly enriched among the list of down-regulated transcripts (Table 2). The most 
13 
 
highly enriched pathway, which remained significant after adjustment for multiple hypothesis 
testing using the conservative Benjamini correction, related to long-term depression (LTD), 
with the related pathway of long-term potentiation (LTP) also identified as significantly 
enriched. These processes relate to a reduction or enhancement, respectively, in synaptic 
strength and efficacy and are key to the process of synaptic plasticity. The list of down-
regulated genes classified in these pathways is given in Table 3. Notably, the long-term 
depression pathway was also identified as down-regulated in our previous study of Hfe
-/-
 
mouse brain (Johnstone et al., 2012b). 
 
There was also significant enrichment, among the list of down-regulated transcripts, of 
various pathways relating to cancer, most notably glioma (Table 2). Most of the genes 
identified in this pathway also form part of the LTD or LTP pathways (Table 3), including 
the important oncogenes v-raf-leukemia (Raf1) and its upstream effector Kirsten rat sarcoma 
(Kras). A similar result was observed in the Hfe
-/-
 mice for Raf1 (1.5-fold decrease in 
transcripts relative to wildtype controls, p=0.028) but not Kras (no significant change, 
p>0.05).  
 




 and dietary iron-
supplemented mice 
As noted above, we have previously published studies of the brain transcriptome in mouse 
models of dietary iron loading (Johnstone and Milward, 2010a) and HFE hemochromatosis 
(Johnstone et al., 2012a; Johnstone et al., 2012b), also aged 10 weeks. Comparison of 
differentially-expressed gene lists from the three different models of iron loading revealed 34 
transcripts common to all lists (Fig. 3). Strikingly, for these 34 transcripts (shown in Table 4), 
across the three models there was 100% concordance in the direction of change relative to 
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wildtype (i.e. transcripts were increased in all models or decreased in all models), much 
higher than the 25% that would be expected by chance alone, suggesting that the majority of 
these findings are not false positives. Of interest, all models showed significantly increased 
transcripts for ferritin light chain 1 and spastin, which is genetically linked to spastic 
paraplegia, and decreased transcripts for the metal binding protein metallothionein 3 (Table 
4). 
 





there was substantial overlap in the list of differentially expressed transcripts, with two-thirds 
of the transcripts identified in Tfr2
mut
 mice also significantly altered in Hfe
-/-
 mice. Again the 
direction of change relative to wildtype was highly consistent, with 96% concordance. We 
focused our validation studies for the Tfr2
mut
 mice on various key transcripts previously 
validated in the Hfe
-/-
 model, including transcripts relating to the LTD or LTP pathways, as 
the consistency observed across different models suggests these are likely to be the most 
robust findings. 
 
We have previously reported increased transcripts by both microarray and real-time RT-PCR 
for the immediate early gene Fos, as well as other genes encoding transcription factors, in 
Hfe
-/-
 mice (Johnstone et al., 2012a). We also observed a large increase in Fos transcripts in 
Tfr2
mut
 mice by microarray (Table 5) and this change was also validated with statistical 






 mice showed significantly decreased transcripts for 
calcium/calmodulin-dependent protein kinase II alpha (Camk2a; Table 5), which has key 
roles in synaptic plasticity and learning and memory and is part of the LTP pathway 
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(Yamauchi, 2005; Lee and Silva, 2009). This was validated by real-time RT-PCR for the 
Tfr2
mut
 model (Fig. 1), having been validated previously in the Hfe
-/-
 mice (Johnstone et al., 
2012a). There were also decreased transcripts in both models for insulin-like growth factor 1 
receptor (Igf1r), involved in LTD and other important brain functions (Bondy and Cheng, 
2004). Again this decrease was validated by real-time RT-PCR in both Tfr2
mut
 mice (Fig. 1) 
and Hfe
-/-
 mice (Johnstone et al., 2012a).  
 
Furthermore, both models show reduced transcripts for the calcium channel gene Cacna1a 
(Table 5), another component of the LTD pathway, and this was also validated by real-time 
RT-PCR (Fig. 1). In humans, the CACNA1A gene is causatively linked to familial hemiplegic 
migraine (Ducros et al., 1999; Hans et al., 1999; Pietrobon, 2002) and may provide an 
intriguing explanation for the increased prevalence of severe headaches reported for people 
with hemochromatosis or brain iron abnormalities (Hagen et al., 2002; Stovner et al., 2002; 
Boes et al., 2006; Gaul et al., 2007). 
 
3.6 Key transcripts identified as altered in Hfe
-/-
 mice but not Tfr2
mut
 mice 
As illustrated by Fig. 3, there were substantially fewer transcripts with altered levels in 
Tfr2
mut
 mice than Hfe
-/-
 mice. We have previously reported altered transcript levels in Hfe
-/-
 
mice for several key genes relating to Alzheimer’s disease (amyloid precursor protein App, 
presenilin 1 Psen1 and other γ-secretase complex components) and Notch signaling (e.g. 
hairy and enhancer of split 1 and 5 Hes1, Hes5) (Johnstone et al., 2012b) but these transcripts 
did not show significantly altered levels by microarray in the Tfr2
mut
 brain (data not shown). 
To confirm that microarray findings of unaltered expression of these two genes in the Tfr2
mut
 
mice, we assessed transcript levels of App and Psen1 in additional wildtype and Tfr2
mut
 mice 
by real-time RT-PCR. While PCR confirmed that App transcript levels were unchanged, 
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Psen1 transcript levels showed a small but significant decrease in Tfr2
mut
 mice relative to 
wildtype controls (Fig. 1), consistent with the finding in Hfe
-/-




This study of the brain transcriptome in the Tfr2
mut 
mouse model of hereditary 
hemochromatosis, together with our previous studies in age-matched dietary iron-
supplemented (Johnstone and Milward, 2010a) and Hfe
-/-
 mice (Johnstone et al., 2012a; 
Johnstone et al., 2012b), provides further evidence that conditions of systemic iron loading 
have detectable influences on brain gene expression. While microarray findings are 
sometimes dismissed because of perceived high potential for false positive findings, the 
observation of common gene expression changes across various models of the same disorder, 
the high degree of concordance in the direction of these changes and the validation of 
changes by real-time RT-PCR strongly supports the assertion that real changes are indeed 




mouse model display a similar iron phenotype to the Hfe
-/-
 and dietary iron-
supplemented mice we have reported previously, with significantly increased liver iron levels 
relative to control mice but no change in brain iron levels. This was confirmed using two 
different methods (non-heme iron assay, ICP-AES). Interestingly, despite the lack of 
detectable brain iron changes, there were increased levels of ferritin protein. Ferritin is 
regulated post-transcriptionally by intracellular iron levels through the iron-responsive 
element/iron regulatory protein (IRE/IRP) system – an increase in ferritin protein in the 
absence of an increase in transcripts is generally indicative of an increase in intracellular 
‘free’ iron (Hentze and Kuhn, 1996; Muckenthaler et al., 2008). The findings may therefore 
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indicate a redistribution of iron within the Tfr2
mut 
mouse brain to favour more iron moving 
into a stored form, either through redistribution between extracellular and intracellular 
compartments or redistribution between subcellular compartments. While there were no 
detectable alterations in transcripts for iron transporters such as ferroportin or divalent metal 
transporter 1 that might mediate these kinds of redistribution, translation of these transcripts 
is also regulated by the IRE/IRP system (Muckenthaler et al., 2008), so changes may only be 
evident at the protein level. 
  
A number of key genes identified in our previously published transcriptomic studies of the 
Hfe
-/-
 mouse model of hemochromatosis (Johnstone et al., 2012a; Johnstone et al., 2012b) 
also showed expression changes in the Tfr2
mut 
mouse model, validating our previous findings 
and providing support for the assertion that disruption of iron homeostasis can lead to 
important changes in the brain. These include effects on genes involved in long-term 
depression, a molecular pathway that was significantly enriched among down-regulated 
transcripts in the two models.  
 
Long-term depression, characterized by a long-lasting decrease in synaptic strength, is a key 
process in neural plasticity and therefore in learning and memory. Findings from animal 
models suggest that brain region-specific disruption of LTD results in a diminished capacity 
for specific types of learning and memory, as reviewed elsewhere (Collingridge et al., 2010). 
As described in more detail by Collingridge and colleagues, LTD is proposed to have roles in 
a range of cognitive functions, including hippocampus-dependent learning and memory 
(Brigman et al., 2010), fear conditioning in the amygdala (Migues et al., 2010), recognition 
memory in the perirhinal cortex (Griffiths et al., 2008) and cerebellar learning (Massey and 




It is therefore conceivable that the reduced expression of key genes relating to LTD observed 
in our mouse models of hereditary hemochromatosis will have a detrimental impact on 
various facets of learning and memory. Behavioural studies of these models, together with 
electrophysiological studies of brain slices to determine net effects on LTD/LTP, will help 
clarify this issue. In addition, it would be valuable to thoroughly assess learning and memory 
in large cohorts of patients with clinical hemochromatosis (i.e. not just individuals with pre-
disposing mutations) and to further investigate suggestions of detrimental effects of high 
hippocampal iron on verbal memory and high basal ganglia iron on working memory 
(Bartzokis et al., 2011). 
 
As far as we are aware, there have been no studies of the effects of iron loading on glioma 
susceptibility, however high expression of TFR2 in glioblastoma biopsies is positively 
correlated with patient survival (Calzolari et al., 2007; Calzolari et al., 2010). It was therefore 
interesting to observe reduced expression of various genes in the ‘glioma’ pathway in Tfr2
mut 
brain, including the important and closely related oncogenes Kras and Raf1. Although 
activating mutations in KRAS and RAF1 are required for oncogenicity or in Noonan 
Syndrome (a common developmental disorder), deletion of either gene in mice causes 
embryonic lethality (Johnson et al., 1997; Huser et al., 2001; Mikula et al., 2001), indicating 
that both genes are essential for normal function. The consequences of reduced expression of 
these genes in the brain is unclear but suggest potentially important effects on the RAS-
MAPK signal transduction pathway, which could have far-reaching effects on the 








mice, there were also a number of differences, with Tfr2
mut 
mice showing far fewer changes 
relative to wildtype controls than Hfe
-/-
 mice. The reasons for this are unclear but may relate 
to differences in the expression patterns of HFE and TFR2 in the brain. Although there are 
few relevant studies to date, HFE transcripts appear to be widely expressed across different 
brain regions, albeit at low levels (Hanninen et al., 2009). In addition, immunohistochemical 
studies have provided preliminary evidence that HFE protein is expressed by brain capillary 
endothelial cells, choroid plexus and ependymal cells (Connor et al., 2001), in addition to 
scattered cells, possibly astrocytes, throughout the cortex and cerebellum (Bastin et al., 
1998).  
 
In contrast, while there has been even less investigation of TFR2 in the brain, some evidence 
suggests that TFR2 expression is confined to the cerebellum in humans (Hanninen et al., 
2009) and that transcripts for TFR2-α are below RT-PCR assay detection limits when 
averaged across the whole mouse brain (Kawabata et al., 1999). The roles of TFR2-α in the 
brain may therefore be restricted to particular regions, notably the cerebellum, while 
disruption of HFE may have the potential to affect systems across a larger number of brain 
regions.  
 
It should be noted, however, that while transcripts for TFR2-α are present at low levels, 
transcripts for TFR2-β are strongly expressed in mouse brain (Kawabata et al., 1999). This 
isoform of TFR2 is not involved in hepcidin regulation but is proposed to be involved in 
transcriptional regulation of the cellular iron export protein ferroportin in the spleen (Roetto 
et al., 2010) and, while its functions in the brain are not known, disruption of the Tfr2 gene 
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and consequently the TFR2-β isoform could potentially have far-reaching effects within the 
brain. 
 
While this study has illuminated several important effects of iron loading disorders on the 
brain, some specific limitations warrant discussion. First, both the evaluations of iron levels 
and the transcriptomic studies focused on whole brain rather than specific regions. Due to 
differences in the distribution and functions of iron across different brain regions and cell 
types, the downstream effects of perturbed iron homeostasis are likely to vary between 
different brain compartments. It will be informative in future studies to investigate 
transcriptomic profiles of particular brain regions to determine if changes are global or 
restricted to certain regions, specifically regions with high concentrations of iron such as the 
basal ganglia (Hallgren and Sourander, 1958; Hill and Switzer, 1984; Bartzokis et al., 1997), 
as well as validating array results at the protein level using immunohistochemistry. In 
addition, it will also be valuable to further characterize the different forms of TFR2 and 




mice showed no net brain iron loading relative to wildtype mice. It is 
therefore important to note that this is not a model for studying the effects of gross brain iron 
accumulation – rather it provides a model for investigating the effects of both systemic iron 
loading in general and TFR2-related iron loading in particular on the brain transcriptome. The 
observed effects may be due to disruption of internal brain systems that normally rely on 
TFR2 or due to peripheral effects of iron loading being transduced to the brain. We plan in 
future studies to investigate models of more severe hemochromatosis, which we expect to 




In summary, the transcriptome perturbations observed in the brains of Tfr2
mut
 mice add to the 
growing body of evidence that disorders of systemic iron loading have important effects on 
the brain. The findings highlight changes to some specific molecular systems, such as long-
term depression, that might partly explain sporadic reports of neurologic sequelae in some 
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Fig. 1. Real-time RT-PCR validation of transcript levels for select genes in Tfr2
mut
 mice. 
Levels of Ftl1, Camk2a, Igf1r, Cacna1a, Fos, App and Psen1 transcripts were determined by 
real-time RT-PCR and expressed relative to the levels of two reference genes (Gapdh, 
Rpl13a). Results are presented as mean ± SEM (n≥8 per group). * p<0.05 relative to wildtype 
mice. 
 
Fig. 2. Ferritin protein levels in Tfr2
mut
 mouse brain. A) Representative Western blot 
showing anti-ferritin immunoreactivity in the wildtype (W) and Tfr2
mut
 (T) mouse brain. 
Actin was used as a reference protein. B) Ferritin levels were quantified by densitometry and 
are expressed relative to actin. Results are presented as mean ± SEM (wildtype n=7, Tfr2
mut
 
n=5). * p=0.01 relative to wildtype mice.  
 









Table 1. Primer sequences for real-time RT-PCR 
Gene name and symbol Forward Primer Reverse Primer 










Calcium channel, voltage-dependent, 





































Table 2. Down-regulated pathways significantly enriched in Tfr2
mut
 brain transcriptome 
Pathway 
Fold 
Enrichment p value 
Benjamini 
p value 





Fc gamma R-mediated phagocytosis 3.8 0.004 0.229 
Phosphatidylinositol signaling system 4.0 0.007 0.241 
Glioma 3.9 0.008 0.207 
Long-term potentiation 3.7 0.010 0.206 
Aldosterone-regulated sodium 
reabsorption 5.6 0.011 0.192 
ErbB signaling pathway 3.6 0.011 0.167 
Pathways in cancer 2.0 0.013 0.174 
Melanogenesis 3.4 0.014 0.174 
Natural killer cell mediated cytotoxicity 3.3 0.017 0.187 
Regulation of actin cytoskeleton 2.3 0.017 0.172 
Calcium signaling pathway 2.4 0.029 0.254 
GnRH signaling pathway 2.9 0.030 0.246 
Insulin signaling pathway 2.6 0.032 0.244 
Gap junction 2.8 0.035 0.247 





Table 3. Down-regulated genes classified in the LTD, LTP or Glioma pathways 





Calcium channel, voltage-dependent, P/Q 
type, alpha 1A subunit Cacna1a 1.7 0.008 
LTD 
Calcium/calmodulin-dependent protein 
kinase II alpha Camk2a 1.5 0.043 
LTP, 
Glioma 
Guanine nucleotide binding protein, alpha O 
Gnao1 1.4 0.009 
LTD 
Glutamate receptor, ionotropic, AMPA2 
(alpha 2) Gria2 1.3 0.036 
LTD, LTP 
Glutamate receptor, ionotropic, AMPA3 
(alpha 3) Gria3 1.4 0.032 
LTD 
Guanylate cyclase 1, soluble, beta 3 
Gucy1b3 1.4 0.001 
LTD 




V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog Kras 1.4 0.044 
LTD, LTP, 
Glioma 
Phospholipase C, beta 1 Plcb1 1.4 0.042 LTD, LTP 
Protein phosphatase 2 (formerly 2A), 
regulatory subunit A (PR 65), alpha isoform 
Ppp2r1a 1.4 <0.001 
LTD 












Ribosomal protein S6 kinase, polypeptide 2 
Rps6ka2 1.3 0.030 
LTP 
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Table 4. Genes with significantly altered expression in all three models of iron loading  
Gene symbol Gene name Fold change  







2310003H01Rik RIKEN cDNA 2310003H01 gene 1.3 1.6 1.2 
2310022B05Rik RIKEN cDNA 2310022B05 gene 1.3 1.5 1.2 
4833439L19Rik RIKEN cDNA 4833439L19 gene -1.4 -1.8 -1.3 
5133401N09Rik RIKEN cDNA 5133401N09 gene 1.3 1.5 1.2 
Apoa1bp Apolipoprotein A-I binding protein 1.3 1.9 1.2 
Arfip2 ADP-ribosylation factor interacting protein 2 -1.3 -3.3 -1.2 
Atp2a1 
ATPase, Ca++ transporting, cardiac muscle, 
fast twitch 1 2.0 2.4 1.5 
Chst10 Carbohydrate sulfotransferase 10 1.5 1.9 1.2 
Coro2b Coronin, actin binding protein, 2B -2.0 -3.1 -1.7 
Doc2b Double C2, beta 1.6 2.0 1.4 
Efemp2 
Epidermal growth factor-containing fibulin-
like extracellular matrix protein 2 1.5 1.7 1.3 
Fam108c 
Family with sequence similarity 108, member 
C 1.6 1.9 1.4 
Fam109a 
Family with sequence similarity 109, member 
A 1.4 1.3 1.3 
Frs3 Fibroblast growth factor receptor substrate 3 1.4 1.8 1.2 
Ftl1 Ferritin light chain 1 1.3 1.3 1.2 
H1f0 H1 histone family, member 0 2.2 3.0 1.6 
Hsdl1 Hydroxysteroid dehydrogenase like 1 1.3 1.8 1.1 
Klhdc1 Kelch domain containing 1 -1.4 -1.9 -1.3 
Litaf LPS-induced TN factor 1.3 1.4 1.2 
Mpv17 
MpV17 mitochondrial inner membrane 
protein -1.3 -1.4 -1.3 
Mrpl13 Mitochondrial ribosomal protein L13 1.5 2.5 1.3 
Mt3 Metallothionein 3 -1.5 -2.1 -1.4 
Nkain4 Na+/K+ transporting ATPase interacting 4 1.6 2.3 1.5 
Pak4 P21 protein (Cdc42/Rac)-activated kinase 4 1.4 2.2 1.2 
Plcb1 Phospholipase C, beta 1 -1.4 -1.4 -1.3 
Polr1c Polymerase (RNA) I polypeptide C 1.4 2.1 1.2 
Psip1 PC4 and SFRS1 interacting protein 1 -1.6 -4.7 -1.5 
Rbm4b RNA binding motif protein 4B 1.3 1.9 1.2 
Slc16a2 
Solute carrier family 16 (monocarboxylic 
acid transporters), member 2 1.8 2.1 1.3 
Smoc1 SPARC related modular calcium binding 1 1.4 1.6 1.3 
Spast Spastin 1.7 2.6 1.2 
Spsb4 
SplA/ryanodine receptor domain and SOCS 
box containing 4 1.5 2.2 1.2 
Ube2ql1 
Ubiquitin-conjugating enzyme E2Q family-
like 1 -1.3 -2.1 -1.2 




Decreased expression relative to control is presented as a negative fold change, increased 









Gene name and symbol Gene functions Fold change  







dependent, P/Q type, alpha 
1A subunit Cacna1a 
LTD, linked to familial 
hemiplegic migraine 
↓ 1.7 ↓ 8.9 
Calcium/calmodulin-
dependent protein kinase IIα 
Camk2a 
LTP, synaptic plasticity, learning 
and memory 
↓ 1.5  ↓ 1.9 
FBJ osteosarcoma oncogene 
Fos 
Transcription factor, marker of 
neuronal activation  
↑ 2.4  ↑ 3.7 
Insulin-like growth factor 1 
receptor Igf1r 
LTD, brain development, anti-
apoptotic properties 
↓ 1.5 ↓ 11.5 
 
↑ = increased transcripts relative to wildtype control, ↓= decreased transcripts relative to 
wildtype control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
